These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 6355100)
1. Insulin-mediated modifications of myocardial lipoprotein lipase and lipoprotein metabolism. O'Looney P; Vander Maten M; Vahouny GV J Biol Chem; 1983 Nov; 258(21):12994-3001. PubMed ID: 6355100 [TBL] [Abstract][Full Text] [Related]
2. Metabolism of VLDL is increased in streptozotocin-induced diabetic rat hearts. Sambandam N; Abrahani MA; Craig S; Al-Atar O; Jeon E; Rodrigues B Am J Physiol Heart Circ Physiol; 2000 Jun; 278(6):H1874-82. PubMed ID: 10843884 [TBL] [Abstract][Full Text] [Related]
3. Metabolism of very-low-density lipoprotein and chylomicrons by streptozotocin-induced diabetic rat heart: effects of diabetes and lipoprotein preference. Niu YG; Evans RD Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1106-16. PubMed ID: 18780778 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein composition as a component in the lipoprotein clearance defect in experimental diabetes. O'Looney P; Irwin D; Briscoe P; Vahouny GV J Biol Chem; 1985 Jan; 260(1):428-32. PubMed ID: 3965456 [TBL] [Abstract][Full Text] [Related]
5. Acute diabetes does not reduce heparin-releasable lipoprotein lipase activity in perfused hearts from Wistar-Kyoto rats. Rodrigues B; Severson DL Can J Physiol Pharmacol; 1993 Sep; 71(9):657-61. PubMed ID: 8313228 [TBL] [Abstract][Full Text] [Related]
6. Myocardial metabolism of triacylglycerol-rich lipoproteins in type 2 diabetes. Niu YG; Evans RD J Physiol; 2009 Jul; 587(Pt 13):3301-15. PubMed ID: 19433573 [TBL] [Abstract][Full Text] [Related]
7. Catabolism of very low density lipoproteins in experimental nephrosis. Garber DW; Gottlieb BA; Marsh JB; Sparks CE J Clin Invest; 1984 Oct; 74(4):1375-83. PubMed ID: 6480830 [TBL] [Abstract][Full Text] [Related]
8. The catabolism of human and rat very low density lipoproteins by perfused rat hearts. Dory L; Pocock D; Rubinstein D Biochim Biophys Acta; 1978 Feb; 528(2):161-75. PubMed ID: 203323 [TBL] [Abstract][Full Text] [Related]
10. Retention of apolipoprotein B and cholesterol by perfused heart during lipolysis of very-low-density lipoprotein. Tam SP; Breckenridge WC Biochim Biophys Acta; 1984 Mar; 793(1):61-71. PubMed ID: 6704414 [TBL] [Abstract][Full Text] [Related]
11. Effects of hormones, amino acids and specific inhibitors on rat heart heparin-releasable lipoprotein lipase and tissue neutral lipase activities during long-term perfusion. Stam H; Hülsmann WC Biochim Biophys Acta; 1984 Jun; 794(1):72-82. PubMed ID: 6375731 [TBL] [Abstract][Full Text] [Related]
12. Endothelial binding sites for lipoprotein lipase are not diminished in perfused hearts from diabetic rats. Liu L; Severson DL Can J Physiol Pharmacol; 1996 Nov; 74(11):1204-9. PubMed ID: 9028578 [TBL] [Abstract][Full Text] [Related]
13. Differences in the metabolism of very-low-density lipoproteins by isolated beating-heart cells and the isolated perfused rat heart. Evidence for collagenase-released extracellular lipoprotein lipase. Rajaram OV; Clark MG; Barter PJ Biochem J; 1980 Feb; 186(2):431-8. PubMed ID: 6246885 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of carnitine palmitoyltransferase 1 by phenylalkyloxiranecarboxylic acid and its influence on lipolysis and glucose metabolism in isolated, perfused hearts of streptozotocin-diabetic rats. Rösen P; Reinauer H Metabolism; 1984 Feb; 33(2):177-85. PubMed ID: 6694560 [TBL] [Abstract][Full Text] [Related]
15. Investigation of the role of serum lipoprotein-associated peroxides in Adriamycin cardiotoxicity. Release of reduced glutathione from rat hearts perfused with lipase-hydrolyzed very low density lipoprotein fractions obtained from Adriamycin-treated and control rats. Thayer WS Biochem Pharmacol; 1989 Jun; 38(12):1923-9. PubMed ID: 2742600 [TBL] [Abstract][Full Text] [Related]
17. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Murdoch SJ; Breckenridge WC Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314 [TBL] [Abstract][Full Text] [Related]
18. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. Schaap FG; Rensen PC; Voshol PJ; Vrins C; van der Vliet HN; Chamuleau RA; Havekes LM; Groen AK; van Dijk KW J Biol Chem; 2004 Jul; 279(27):27941-7. PubMed ID: 15090553 [TBL] [Abstract][Full Text] [Related]
19. Ex vivo measurement of lipoprotein lipase-dependent very low density lipoprotein (VLDL)-triglyceride hydrolysis in human VLDL: an alternative to the postheparin assay of lipoprotein lipase activity? Pruneta V; Autran D; Ponsin G; Marcais C; Duvillard L; Verges B; Berthezene F; Moulin P J Clin Endocrinol Metab; 2001 Feb; 86(2):797-803. PubMed ID: 11158049 [TBL] [Abstract][Full Text] [Related]